Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- PII of Riociguat for PH-ILD, PH-COPD Completed: Bayer
January 4, 2010
- MOF Demands Double-Digit Cut in Prices of Long-Listed Drugs
January 4, 2010
- NIBIO to Start Supplying iPS Cells to Private Companies
January 4, 2010
- Ethical Drugs Sales Up 6.2% Driven by Flu Vaccines: Crecon
January 4, 2010
- Health Minister Optimistic about Increases in Medical Fees after Tete-a-Tete with Finance Minister
January 4, 2010
- Carna Biosciences’Colon Cancer Research Project Subsidized by JST
January 4, 2010
- Takeda Licenses Brentuximab from Seattle Genetics
January 4, 2010
- Victoza, Bridion Recommended for Approval
January 4, 2010
- Chuikyo Recommends Approval of Proposed System Reform for Insurance-Covered Medical Materials
January 4, 2010
- Astellas Licenses FLT3 Inhibitors from Ambit Biosciences
January 4, 2010
- New Premium Intended to Strengthen Japanese Pharmas: Mr Kinoshita
January 4, 2010
- CMIC Licenses L-FABP to Roche
January 4, 2010
- DSP Undertakes Sweeping Reorganization to Enhance Its Presence in CNS Field
January 4, 2010
- Chuikyo Recommends Unification of Revisit Consultation Fee for Clinics and Hospitals
January 4, 2010
- IBL Launches Human Amyloidβ (1-38) Assay Kit
January 4, 2010
- Takeda to Copromote Actos with Pfizer in China
January 4, 2010
- DPJ Calls For Net Increases in Medical Fees
January 4, 2010
- No Serious Concern about Safety of New-Type Flu Vaccines Made in Japan
January 4, 2010
- AZ Aims at Top Share for Asthma with Symbicort
January 4, 2010
- Merck Serono Aims at 10% Market Share for hGH Saizen
December 21, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…